KDM6B通过MAPK信号通路调控肾癌细胞的增殖和迁移

Effects of the biological function of KDM6B on clear cell renal cell carcinoma

目的研究赖氨酸特异性去甲基酶6B(KDM6B)表达对肾透明细胞癌增殖和迁移侵袭的影响。方法通过基因表达谱交互分析数据库分析KDM6B表达与肾透明细胞癌临床分期与预后的关系。将肾透明细胞癌患者的肿瘤组织石蜡切片进行KDM6B免疫组化染色并统计与临床病理特征的相关性,使用敲低对照小干扰RNA以及敲低KDM6B小干扰RNA对人肾透明细胞癌细胞株ACHN和Caki-1细胞分别进行转染,使用实时荧光定量聚合酶链式反应(RT-qPCR)及Western blot验证转染效率,使用CCK8实验检测转染后肾透明细胞癌细胞增殖能力的变化,克隆形成实验检测细胞形成克隆的能力,使用Transwell实验检测细胞迁移侵袭能力的变化。使用Western blot实验检测丝裂原活化蛋白激酶(MAPK)信号通路中磷酸化的细胞外信号调节激酶蛋白(p-ERK)及细胞外信号调节激酶蛋白的表达水平。结果肾透明细胞癌组织中KDM6B的高表达与良好的疾病分期与预后密切相关。在两种细胞系中转染siKDM6B均能成功敲低KDM6B的表达。敲低KDM6B表达后肾透明细胞癌细胞ACHN和Caki-1的细胞增殖能力显著增强,细胞克隆形成能力明显增强,细胞迁移侵袭能力显著增强。敲低KDM6B表达后p-ERK表达水平显著增加。结论KDM6B抑制MAPK信号通路激活及肾透明细胞癌细胞进展,该蛋白可能成为诊断肾透明细胞癌的生物标记物以及治疗肾透明细胞癌的潜在靶点。

Objective To study the effect of lysine specific demethylase 6B(KDM6B)expression on the proliferation,migration and invasion of clear cell renal cell carcinoma(ccRCC).Methods GEPIA website was used to analyze the relationship between KDM6B expression and pathological stage and prognosis of ccRCC.Human ccRCC cell lines ACHN and Caki-1 were cultured,and siNC and siKDM6B small interfering RNA were synthesized.ACHN and Caki-1 cells were transfected by siRNA.The transfection efficiency of ACHN and Caki-1 cells was verified by RT-qPCR and Western blot.The proliferation ability of the transfected ccRCC cells was detected by CCK8 assay.Colony formation assay was used to detect the ability of cells to form clones,and transwell assay was used to detect the migration and invasion of cancer cells.Western blot assay was used to detect MAPK signaling pathway and its changes.Results The high expression of KDM6B in patients with ccRCC was closely related to earlier disease stage and better prognosis.The expression of KDM6B was successfully knocked down by siKDM6B in both cell lines.Knockdown of KDM6B expression significantly enhanced the proliferation ability,cell clonogenesis ability,and cell migration and invasion ability of ccRCC cells ACHN and Caki-1.After knockdown of KDM6B expression,p-ERK expression level increased significantly.Conclusions KDM6B suppresses the MAPK signaling pathway and the cancer progression in ccRCC,which may be a biomarker for the diagnosis of ccRCC and a potential target for the treatment of ccRCC.